[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 161, "maxAge": 86400, "priceHint": 2, "previousClose": 7.23, "open": 7.29, "dayLow": 6.42, "dayHigh": 7.29, "regularMarketPreviousClose": 7.23, "regularMarketOpen": 7.29, "regularMarketDayLow": 6.42, "regularMarketDayHigh": 7.29, "beta": 0.924, "forwardPE": -4.850746, "volume": 398147, "regularMarketVolume": 398147, "averageVolume": 221991, "averageVolume10days": 205220, "averageDailyVolume10Day": 205220, "bid": 6.47, "ask": 6.54, "bidSize": 200, "askSize": 200, "marketCap": 343608192, "fiftyTwoWeekLow": 1.93, "fiftyTwoWeekHigh": 9.69, "priceToSalesTrailing12Months": 23.19796, "fiftyDayAverage": 8.1308, "twoHundredDayAverage": 5.92625, "currency": "USD", "enterpriseValue": 272588224, "floatShares": 26080393, "sharesOutstanding": 48586200, "sharesShort": 381761, "sharesShortPriorMonth": 419685, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0072000003, "heldPercentInsiders": 0.008640001, "heldPercentInstitutions": 0.84744, "shortRatio": 1.59, "shortPercentOfFloat": 0.01, "impliedSharesOutstanding": 5143130, "bookValue": 2.567, "priceToBook": 2.5321388, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -96797000, "trailingEps": -0.75, "forwardEps": -1.34, "enterpriseToRevenue": 18.403, "enterpriseToEbitda": -2.811, "52WeekChange": 1.4621212, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "messageBoardId": "finmb_583057578", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.5, "targetHighPrice": 15.0, "targetLowPrice": 10.0, "targetMeanPrice": 12.57, "targetMedianPrice": 12.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 162783008, "totalCashPerShare": 3.079, "ebitda": -96972000, "totalDebt": 91763000, "quickRatio": 5.171, "currentRatio": 5.233, "totalRevenue": 14812000, "debtToEquity": 74.624, "revenuePerShare": 0.178, "returnOnAssets": -0.30793, "returnOnEquity": -0.96322995, "freeCashflow": -43514248, "operatingCashflow": -67038000, "revenueGrowth": -0.917, "operatingMargins": -55.429333, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]